UPCC 34810 The Cardiovascular Effects of Sunitinib Therapy: Off-Target Changes in Cardiac Metabolism and Ventricular-Vascular Mechanics (CREST)

Site Image

Study Overview

Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. However, the mechanisms of these effects in humans remains poorly defined, as are the clinical methods to risk stratify and identify patients who will ultimately suffer from cardiac dysfunction. The goal of this multi-center pilot study is to characterize the cardiovascular changes that occur with sunitinib through a detailed examination of: 1) sensitive echocardiographic measures of cardiac function; 2) comprehensive measures of arterial function and left ventricular afterload; 3) biomarkers reflective of the pathophysiologic alterations. Through this work, we will translate our basic science understanding of sunitinib cardiotoxicity to humans and identify early predictors of sunitinib cardiotoxicity.

  • Study Identifier: 812935

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu